Kif18a inhibitors

A compound of formula I:

• or any pharmaceutically-acceptable salt thereof, wherein:
• L is —(C═O)—NR8— or —NR8—(C═O)—;
• R1 is a group —Z—R9;
• wherein Z is absent, —NR11—, —NR11SO2—C1-4alk-, —NR11SO2NR11, —NR11SO2NR11—C(═O)—O—, —N═S(═O)<, —SO2NR11—C0-4alk-, C0-4alk-S(═O)(═NH)—, C0-4alk-S(═O)(═N+(CH3)2)—, C1-4alk-, C0-4alk-S—, C0-4alk-S(═O)—, C0-4alk-SO2—, —O—, —P—, —P(═O), —P(═O)2, —(C═O)—, —(C═O)NR11—, —C═N(OH)—, or —NR11(C═O);
• R2 is a group —Y—R10, wherein Y is absent, C0-4alk-S—, C0-4alk-S═O, C0-4alk-S(═O)2, —SO2NR10c—C0-4alk-, —NR10c—, —NR10c—SO2—C0-4alk-, —C0-4alk-S(═O)(═NH)—, —O—C0-4alk-, —(C═O)—, —C0-4alk-(C═O)—O—, or —N═S(═O)<;
• R3 is H, halo, C1-4alk, or C1-4haloalk;
• R4 is H, halo, C1-4alk, or C1-4haloalk;
• R5 is H, halo, C1-8alk, or C1-4haloalk;
• R6 is H, halo, C1-8alk, or C1-4haloalk;
• R7 is H, halo, C1-4alk, or C1-4haloalk;
• R8 is H or C1-4alk;
• R9 is H, R9a, or R9b;
• R10 is halo, R10a or R10b;
• RX is selected from
• or RX is an C2-8alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, —CH2F, —CHF2, —CF3, —C(═O)ORa, —ORa, —OC1-4haloalk, CN, NH2, NH(CH3), N(CH3)2, or RXm;
• or RX is phenyl or unsaturated 5-membered monocyclic ring substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, —C1-6alk, —C1-6haloalk, —C(═O)ORa, —ORa, —OC1-4haloalk, CN, NH2, NH(CH3), N(CH3)2, or RXm;
• wherein said 5-membered monocyclic ring contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S;
• Each of RXa, RXb, RXc, RXd, RXe, RXf, RXg, RXh, RXi, RXj, RXk, and RXl is H, halo, RXn, or RXo;
• or alternatively, each of RXa and RXb pair, RXc and RXd pair, RXe and RXf pair, RXg and RXh pair, RXi and RXj pair, and RXk and RXl pair, independently, can combine with the carbon atom attached to each of them to form a saturated or partially-saturated 3-, 4-, 5-, 6-membered monocyclic ring spiro to the azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or azepanyl ring;
• wherein said 3-, 4-, 5-, 6-membered monocyclic ring contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, and further wherein said 3-, 4-, 5-, 6-membered monocyclic ring is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —NRaRa, or oxo;
• Each RXm and RXn is independently, at each instance, selected from the group consisting of a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2, 3, or 4 group(s) selected from F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)R, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)R, —OC(═O)NRaRa, —OC2-6alkNRaRa, —OC2-6alkORa, —SRa, —S(═O)R, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)R, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa, —NRaC2-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, and oxo;
• RXo is independently, at each instance, selected from the group consisting of C1-8alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, —CH2F, —CHF2, —CF3, —C(═O)ORa, —ORa, —OC1-4haloalk, CN, NH2, NH(CH3), or N(CH3)2;
• R9a and R10a is independently, at each instance, selected from the group consisting of a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 group(s) selected from F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)R, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)R, —OC(═O)NRaRa, —OC2-6alkNRaRa, —OC2-6 alkORa, —SRa, —S(═O)R, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa, —NRaC2-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)R, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa, R11, and oxo;
• R9b and R10b is independently, at each instance, selected from the group consisting of C1-6alk substituted by 0, 1, 2, 3, 4, or 5 group(s) selected from F, Cl, Br, —CH2F, —CHF2, —CF3, —C(═O)ORa, —ORa, —OC1-4haloalk, CN, NH2, NH(CH3), or N(CH3)2;
• R10c is H or C1-4alk;
• R11 is H or C1-8alk;
• Ra is independently, at each instance, H or Rb;
• and
• Rb is independently, at each instance, C1-6alk, phenyl, or benzyl, wherein the C1-6alk is being substituted by 0, 1, 2 or 3 substituents selected from halo, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk;
• and the phenyl or benzyl is being substituted by 0, 1, 2 or 3 substituents selected from halo, C1-4alk, C1-3haloalk, —OH, —OC1-4alk, —NH2, —NHC1-4alk, —OC(═O)C1-4alk, or —N(C1-4alk)C1-4alk.